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BACKGROUND. Aging remains one of the single greatest risk factors for the devel-
opment of new breast carcinoma. The aim of the study was to evaluate the relation
between biologic features at ﬁrst diagnosis of breast carcinoma and treatment
choice for postmenopausal women 50 years to optimize treatment in the elderly.
METHODS. The sample included 2999 consecutive postmenopausal patients re-
ferred for surgery at the European Institute of Oncology (Milan, Italy) from April
1997 to February 2002. The patients were grouped according to age: young post-
menopausal (YPM; 50–64 years, n  2052), older postmenopausal (OPM; 65–74, n
 801), and elderly postmenopausal (EPM;  75, n  146).
RESULTS. EPM patients referred to surgery had larger tumors compared with YPM
patients (pT4: 6.7% vs. 2.4%) as well as greater lymph node involvement (lymph
node positive: 62.5% vs. 51.3%). EPM patients showed a higher degree of estrogen
and progesterone receptor expression (P  0.01), less peritumoral vascular inva-
sion (P  0.01), and less HER-2/neu expression (P  0.01) than YPM patients.
Comorbidities were more often recorded for elderly patients (72% EPM vs. 45%
YPM; P 0.001), did not inﬂuence surgical choices, and were similar across groups
(breast conservation: 73.9%, 76.9%, and 72.9%, respectively). No systemic therapy
(either chemotherapy or endocrine therapy) was recommended for 19.1% of the
EPM compared with 5.4% and 4.7% of the two other groups.
CONCLUSIONS. In spite of larger tumor size at presentation, older patients had
tumors with more favorable biologic characteristics, when compared with younger
postmenopausal patients. Reluctance to prescribe systemic treatments was due to
the complexity of evaluation for these patients. Taking into account the data from
the current study and given the climate of uncertainty regarding optimal treat-
ment, the authors decided to individualize care on the basis of biologic character-
istics, comorbidity, social support, functional status, and patient preferences.
Trials of tailored adjuvant therapy should be a health care priority. Cancer 2004;
101:1302–10. © 2004 American Cancer Society.
KEYWORDS: breast carcinoma, elderly patients, postmenopausal, treatment, breast-
conserving surgery.
Breast carcinoma is the most common form of malignant diseaseamong women in most of the developed world, and aging remains
one of the single greatest risk factors for the development of new
breast carcinoma. Approximately 50% of breast carcinomas occur in
women  65 years, and  30% of breast carcinomas occur among
women  70 years.1 Older women represent the fastest growing
segment of the population in the United States and in Europe.2
Therefore, during the coming decades, older women will represent an
increased cohort of both patients with newly diagnosed disease and
survivors.3,4 These older survivors of breast carcinoma are likely to be
a somewhat heterogeneous group, especially with respect to multiple
comorbid conditions.5,6 Currently, treatment for elderly women with
breast carcinoma is largely extrapolated from data derived from trials
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comprising younger patients, which is thus variable
and represents evolving paradigms.7–11 Decisions
about optimal treatment patterns will ultimately de-
pend on trial data regarding efﬁcacy and women’s
treatment preferences.12 There are scant data on the
long-term sequelae of different breast carcinoma
treatments to guide older women who are facing these
important decisions.13 Improvements in life expect-
ancy increase the incentive to allow older women with
breast carcinoma to be treated without major barriers
related to age, functional status, and social support.
One way to assess such features is provided by group-
ing the older cohorts according to the need for reha-
bilitative intervention.14 A formal geriatric assessment
is used only rarely to aid the decision-making process
for cancer treatment. Subjective evaluation and per-
sonal prejudices of the physician often guide the ther-
apeutic approach for older women.15–17
Objective assessments and a standardized ap-
proach are usually available in large cancer institutes,
rather than in smaller centers. Larger institutes usually
beneﬁt from a geriatric service. It is important to ac-
knowledge the pioneering work of geriatric oncolo-
gists who endeavored to bridge the gap. In the prog-
nostic assessment of breast carcinoma in elderly
women, two aspects need to be considered, i.e., “seed”
and “ground” effects.18 The seed reﬂects the tumor
itself and its biology, which includes factors such as
the increased prevalence of endocrine responsiveness,
low proliferation rate, and the prevalence of well dif-
ferentiated tumors. Less is known about the ground or
“soil” effects. The ground effects refer to immune se-
nescence, neoangiogenesis, and to the availability of
growth hormones.
Immunohistochemical determination of HER-2/
neu, steroid hormone receptors, proliferation fraction,
and vascular invasion have not been studied system-
atically and speciﬁcally for the upper age groups.
The aims of the current study were to describe the
characteristics and treatment of women  50 years
diagnosed with breast carcinoma and to compare
women who are young postmenopausal (50–64 years)
with those who are old postmenopausal (65–74 years)
and elderly postmenopausal ( 75 years). Under-
standing breast carcinoma in these age groups is sig-
niﬁcant because of the relative lack of research on
breast carcinoma treatment in the elderly women. The
current report describes such features in an attempt to
plan future studies and, thereby, improve treatments
for elderly patients.
MATERIALS AND METHODS
We evaluated 2999 consecutive postmenopausal pa-
tients with breast carcinoma referred for surgery at the
European Institute of Oncology in Milan between
April 1997 and February 2002. Data on patient medical
history, concurrent diseases, surgery, pathology, and
results of staging procedures (e.g., bone scan, chest
X-ray, abdominal ultrasound) were recorded. Pathol-
ogy investigations included evaluation of the primary
tumor and lymph node and/or sentinel lymph node
when applicable.19 Tumor grade was evaluated ac-
cording to Elston and Ellis20 and peritumoral vascular
invasion (PVI) was assessed according to Rosen and
Oberman.21 Estrogen receptor (ER) level, progesterone
receptor (PgR) level, and Ki-67 labeling index (deter-
mined with the MIB-1 monoclonal antibody) were
evaluated immunocytochemically as previously re-
ported.22 HER-2/neu overexpression was evaluated
immunocytochemically using a 1:100 dilution of a
polyclonal antiserum (Dako, Glostrup, Denmark).
Overexpression was considered to have occurred if
 10% of neoplastic cells had complete membrane
staining. For evaluation of ER, PgR, and the Ki-67
labeling index, the percentage of cells exhibiting def-
inite nuclear staining over  2000 neoplastic cells
examined at  400 magniﬁcation was recorded. The
slides were evaluated independently by two of the
authors. The threshold values for HER-2/neu overex-
pression and for overexpression of ER and PgR were
10% and 20% for MIB-1, respectively, as previously
reported.22 Grading was not provided by pathologists
for the group of patients who underwent preoperative
chemotherapy due to the interference of the treat-
ment with architectural and cytologic features of the
tumor. Staining for HER-2/neu overexpression was
only performed routinely after September 1999. All the
data were stored in a Microsoft Access database and
constantly checked for consistency on a weekly basis,
by comparing it with the original data from the patient
clinical chart. The database was used for interdiscipli-
nary discussion (i.e., among surgeons, pathologists,
medical oncologists, and radiation oncologists) and
resulted in a proposal for postoperative adjuvant
treatments.
Surgical Procedures
Patients underwent surgery either by quadrantectomy
with sentinel lymph node biopsy and/or complete
axillary lymph node dissection (ALND) or by modiﬁed
radical mastectomy for breast carcinoma. Wide breast
resection or quadrantectomy was performed using a
radial skin incision centered on the palpable tumor or
a periareolar incision for tumors close to the areola.
For patients with nonpalpable lesions, we performed
radio-guided surgery by a radioisotopic localization
with 99mTc as previously described.23 Patients with
inﬁltrating single tumors  3 cm in diameter and with
clinically negative axillary lymph nodes underwent
breast-conserving surgery and sentinel lymph node
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biopsy. Otherwise, a complete ALND was performed.
Sentinel lymph node biopsy or ALND was performed
through the same incision in patients who received
upper outer breast resection or through a counter
incision for other tumor sites.
Primary Chemotherapy
Patients with large or locally advanced breast carci-
noma (cT2–4) were treated with several chemother-
apy regimens for a treatment duration of up to six
courses. All patients had biopsies performed through
Tru-cut (C.R. Bard, Inc., Covington, GA) and were
evaluated after standard ﬁxation before treatment.
The treatment was based on tumor characteristics.
Statistical Analysis
The aim of the current analysis was to compare tumor
characteristics, biologic markers, and multidisci-
plinary treatments among three groups of patients:
young postmenopausal (YPM; 50–64 years), older
postmenopausal (OPM; 65–74 years), and elderly post-
menopausal (EPM; women  75 years). ER, PgR, and
KI-67 were categorized into their clinically accepted
groups. There are no clinically relevant categories for
HER-2/neu, which was split into two groups at the
10% level. The associations between categorical vari-
ables and age group were measured in contingency
tables using two-sided chi-square tests of associations.
The Kruskal–Wallis test was used to measure quanti-
tative biologic markers. We performed a binary logistic
and multinomial regression analyses to estimate the
interdependence of tumor characteristics, biologic
features (both as categorical and continuous vari-
ables), and age on treatment. The ﬁnal model con-
tained the characteristics and features that were sig-
niﬁcant at the 5% level. Interaction tests were used to
investigate the homogeneity of effects over the three
age groups.
RESULTS
A total of 2999 postmenopausal patients with breast
carcinoma who underwent surgery were referred for a
multidisciplinary evaluation. Of these, 2052 patients
(68.4%) were classiﬁed as YPM, 801 (26.7%) were clas-
siﬁed as OPM, and 146 (4.9%) were classiﬁed as EPM.
Table 1 summarizes the tumor characteristics accord-
ing to age. Patients in the EPM group had larger tu-
mors at diagnosis than younger patients (Table 1).
Lymph node involvement was greater among EPM
women compared with YPM women (62.5% vs. 51.3%;
Table 1). Histology was the same in all age groups,
although mucinous carcinoma was slightly increased
in the EPM group compared with the YPM and OPM
patients (Table 1). In spite of the larger tumors at
presentation, older patients had tumors with more
favorable biologic characteristics compared with
younger patients (i.e., a higher degree of ER and PgR
receptor expression, less PVI, and less HER-2/neu ex-
pression; Table 1). Receptor expression was similar
among the three groups (80.8% vs. 83.7% vs. 81.9%,
respectively, for the YPM, OPM, and EPM patients),
although a larger percecntage of OPM patients had a
higher degree of ER and PgR expression in the tumor
( 10% of cells: 39.7–48.4% and 54.9%, respectively; P
 0.01). HER-2/neu positive was associated with age
(P  0.01), and the percentage of women who were
HER-2/neu was negatively associated with age. PVI
decreased with age from 31% in the YPM group to 25%
in the EPM group (Table 1; P 0.02). However, neither
grade (P  0.89) nor Ki-67 labeling index (P  0.56)
was associated with age (Table 1).
As expected, the incidence of comorbidities was
greater among EPM patients—24% reported no co-
morbidities compared with 54.8% and 35.7% of the
other groups. In the EPM group, the most common
condition with a high impact of comorbidity was hy-
pertension under active treatment (22.6%). Cardiovas-
cular diseases were observed in 20.5% of the patients.
Diabetes occurred in 0.7% of EPM patients. Two or
more comorbid conditions occurred in 21.2% of EPM
patients.
One hundred and ninety-ﬁve patients (6.5%) re-
ceived preoperative chemotherapy—195 in the YPM
group (9.5%), 31 in the OPM group (3.9%), and 1
patient in the EPM group (0.7%). Surgical approaches
were similar in the 3 groups of patients (P  0.47;
Table 2). For women who underwent breast-conserv-
ing surgery, radiotherapy was recommended to only
54.7% of elderly patients ( 75 years), compared with
84.5% of older women (65–75 years) and 86.6% of
younger patients (50–64; P 0.01). For clarity, the
younger patients received a standard radiotherapy
regimen when indicated, with the exception of women
who were treated with intraoperative radiotherapy as
participants in an institutional trial or women who
received conﬁrmation during postsurgical follow-up
and/or workup for a suspicious metastatic lesion.
Chemotherapy was recommended to 6.4% of women
in the EPM group compared with 35.4% of women in
the other two groups. For ER-positive patients, endo-
crine treatment was recommended to 74.4% of the
EPM women compared with 72.5% of YPM women
and 82.0% of OPM women. Decision-making was ori-
ented to recommend no systemic therapy (either che-
motherapy or endocrine therapy) to 19.1% of EPM
patients compared with 5.4% and 4.7% of YPM and
OPM patients (Table 2).
The choice of adjuvant therapies depended on
medical decisions inﬂuenced by grade, stage, ER sta-
tus, lymph node status, and comorbid condition.
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TABLE 1
Description of Biologic Characteristics, Histology, Pathologic Stage of Breast Tumors and Comorbid Illness in Postmenopausal Women
Diagnosed with Breast Carcinoma at the Europe Institute of Oncology in Milan April 1997–February 2002 (n  2999)
Factors YPM OPM EPM Two-sided P valueb
No. of patients evaluable for ER/PgR 1913 773 144
Percentage ER  10% 21.4 17.5 18.8 0.07
ER  10% 78.6 82.5 81.3
Percentage PgR  10% 47.5 40.1 38.2  0.01
PgR  0 10% 52.5 59.9 61.8
ER and PgR negative 19.1 16.3 18.1
ER or PgR  10% 41.2 35.3 27.1
ER and PgR  10% 39.7 48.4 54.9  0.01
No. of patients evaluable for Ki-67 proliferative index 1851 758 138
Ki-67  20% 51.3 53.3 54.3
Ki-67  20% 48.7 46.7 45.7 0.56
No. of patients evaluable for PVI 1845 749 130
Percentage PVI present 30.6 25.5 24.6  0.02
No. of patients evaluable for grade 1576 678 116
1 18.8 17.7 16.4
2 47.6 49.3 50.9
3 33.6 33.0 32.8 0.89
No. of patients evaluable for HER-2/neu 1105 422 107
HER-2/neu  0 57.3 66.1 64.6
HER-2/neu  10%a 1.9 0.7 2.8
HER-2/neu  10% 40.8 33.2 32.7  0.01
Histology
No. of patients evaluable 1966 783 146
Inﬁltrating ductal (%) 74.2 72.3 71.9
Inﬁltrating lobular (%) 10.1 11.2 10.3
Cribriform (%) 2.4 1.6 2.4
Mucinous (%) 1.1 2.8 4.1
Tubular (%) 1.1 1.1 0
Other (mixed tumors and rare subtypes) 11.1 10.0 12.3 0.81
Pathologic stage (pTNM)
No. of patients evaluable for pT 1864 748 134
pT0 2.4 1.5 0.7
pT1 62.8 56.6 45.5
pT2 28.9 35.6 44.8
pT3 3.6 3.9 2.2
pT4 2.4 2.5 6.7  0.01
No. of patients evaluable for pN 1806 741 96
pN0/sentinel node negative 48.9 47.1 37.5
pN1 48.3 49.9 52.1
pN2 2.8 3.0 10.4  0.01
No. of patients evaluable for positive lymph nodes
No. of positive lymph nodes 1814 742 95
0 48.9 47.1 37.5
1–3 28.6 34.1 26.7
4–9 10.7 8.5 13.7
 10 11.8 10.3 22.1  0.01
No. of patients evaluable for comorbid illness 2052 801 146
Percentage with hypertension (%) 12.7 21.5 22.6
Percentage with cardiovascular disease (%) 4.1 12.9 20.5
Percentage with diabetes (%) 0.9 1.4 0.7
Two or more comorbid conditions 10.5 13.4 21.9  0.01
PVI: peritumoral vascular invasion; YPM: young postmenopausal women; OPM: older postmenopausal women; EPM: elderly postmenopausal women; ER: estrogen receptor; PgR: progesterone receptor.
a refers to complete staining of the membrane.
b The P values are taken from a chi-square test for association or equality of proportions.
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Many of these variables were themselves related to
age. Consequently, the association with age may just
be a reﬂection of the tumor characteristic associa-
tions, and this is investigated in the multinomial lo-
gistic regression models (Table 3). Adjusting for ER
status, PgR status, comorbidity, Ki-67 labeling index,
and PVI, there was still a signiﬁcant association be-
tween age group and the propensity to receive sys-
temic therapy. All variables in the multinomial regres-
sion model were independently associated with
receiving systemic therapy (P  0.05) with the sole
exception of comorbidities (P  0.08).This is expected
as these variables are part of the clinical decision-
making process. Adjusting for these variables, women
in the EPM group are less likely to receive any sys-
temic therapy, (P  0.01). Compared with a woman in
the EPM group, a woman in the YPM has an odds ratio
(OR) of 0.008 (95% conﬁdence interval [CI], 0.002,
0.039) of receiving no systemic therapy and a woman
in the OPM group has an OR of 0.020 (0.004, 0.106) of
receiving no systemic therapy.
Similar multinomial models revealed that the type
of surgery received was not inﬂuenced by the age of
the patient but was dictated by tumor characteristics.
Women in the EPM group are less likely to receive
radiotherapy (P  0.01). Compared with a woman in
the EPM group, a woman in the YPM group has an OR
of 0.47 (95% CI 0.27, 0.75) of not receiving radiother-
apy and a woman in the OPM group has an OR of 0.50
(0.29, 0.85) of receiving no radiotherapy.
DISCUSSION
The study described the characteristics and treatment
of women  50 years diagnosed with breast carci-
noma and compared YPM women (50–64 years) with
OPM women (65–74 years) and EPM women ( 75
years). We observed that even if elderly patients re-
ferred to surgery had larger tumors and greater lymph
node involvement compared with younger women
with smaller tumors and less lymph node involve-
ment, they have a more favorable biologic tumor pro-
ﬁle overall. Comorbidities were more often recorded
in elderly patients compared with younger patients,
but these did not inﬂuence surgical treatment but
affected adjuvant treatments. Moreover, the subjects
include a large sample from a recent period , reducing
bias related to changes in incidence and treatment
over time.
Although available age-speciﬁc clinical data dem-
onstrate that treatment efﬁcacy is not modiﬁed by age,
elderly patients are underrepresented in cancer clini-
cal trials.24,25 Older patients are more likely to have
conditions that make them ineligible for clinical trials
because of protocol exclusions mainly related to co-
morbidities or ageist trial designing.26 The results of a
recent analysis27 showed that 32% of participants in
Phase II and III clinical trials were elderly, compared
with 61% of patients with incident cancers in the
United States who are elderly. The degree of under-
representation was more pronounced in trials for ear-
ly-stage rather than for late-stage cancers. Protocol
exclusion criteria on the basis of organ system abnor-
malities and functional status limitations were associ-
ated with lower elderly participation. An analysis of
16,396 patients consecutively enrolled in 164 clinical
trials under the auspices of the Southwest Oncology
Group during the years 1993–1996 demonstrated that
elderly patients were generally underrepresented in
treatment protocols compared with the general cancer
population (25% vs. 63%). This was mainly evident for
patients with breast carcinoma.28 Indeed, despite the
ﬁnding that patients with breast carcinoma 65 years
accounted for 49% of the entire breast carcinoma pop-
ulation cohort in trials, only 9% of them were included
in treatment protocols. This ﬁnding was due to the
attitude of clinicians who proposed participation in
clinical trials to only a few elderly patients and ex-
cluded them from treatment for comorbid conditions,
and to the risk of excessive toxicity of systemic treat-
ment. This attitude is also related to the widespread,
although controversial, impression among clinicians,
that breast carcinoma in younger women is an aggres-
sive disease, whereas it is indolent among older
women. Against such prejudices, several reports29,30
illustrated a signiﬁcant beneﬁt of disease-free survival
after treatment with tamoxifen.31,32 The opportunity
to be able to tailor treatments according to several
biologic features (e.g., hormone receptors, c-erb-B2
overexpression, multicentricity) leads to an increasing
TABLE 2
Local and Systemic Treatment in Percentage of Patients in Relation
to Age Groups
Type of treatment YPM OPM EPM Two-sided P value
Surgery
No. of patients evaluable 2051 801 146
BCS (%) 73.9 76.9 72.6
mastectomy (%) 22.3 20.2 23.3
other (%) 3.8 2.9 4.1 0.47
Radiotherapy in BCS
No. of patients evaluable 1506 613 104
receiving RT (%) 86.6 84.5 54.7  0.01
Systemic therapy
No. of patients evaluable 2032 795 141
no treatment (%) 4.7 5.4 19.1
CT only 22.8 12.6 6.4
HT only 37.3 58.4 71.6
CT  HT 35.2 23.6 2.8  0.01
YPM, OPM, EPM: younger, older, elderly pastmenopausal patients; BCS: breast-conserving surgery; RT:
radiotherapy; CT: chemotherapy; HT: hormone therapy.
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need for an accurate biologic characterization of
breast carcinoma, even for elderly women. Patients in
the EPM group had larger tumors (pT4) compared
with patients in the YPM group (6.7% vs. 2.4%) as well
as greater lymph node involvement (62.5% vs. 51.3%).
Information in the literature either conﬁrms33 or re-
jects34 this observation, indicating the controversy re-
lated to lymph node involvement. Our cohort was
collected over a period of time in which accuracy in
evaluating lymph node involvement increased due to
sentinel lymph node staging.35 This might account for
the heterogeneity of reporting on lymph node involve-
ment across series. Other hypotheses related to delay
in diagnosis should also be considered.36 This may
reﬂect reduced breast awareness among older women,
who are less likely to self-examine37 and may also be
due to lack of mammographic screening.
Surgical approaches to elderly and to younger pa-
tients were similar in our institution, in keeping with




No CT or HT CT only HT Only
OR LCL UCL OR LCL UCL OR LCL UCL
YPM 0.0077 0.0015 0.0392 0.487 0.007 3.391 0.0394 0.0094 0.165
OPM 0.0201 0.0038 0.106 0.16 0.022 1.116 0.104 0.0244 0.444
EPM 1 1 1
ER and PgR negative 250.023 49.069 1273.943 1569.886 343.496 7174.875 0.393 0.0539 2.869
ER or PgR  10% 1.317 0.643 2.738 2.945 1.645 5.283 0.594 0.448 0.789
ER and PgR  10% 1 1 1
No comorbidities 0.575 0.236 1.4 1.751 0.755 4.063 0.73 0.472 1.128
CV comorbidities 0.459 0.177 1.195 1.335 0.518 3.438 0.659 0.408 1.064
Non CV comorbidities 0.995 0.351 2.821 1.256 0.456 3.435 1.046 0.619 1.77
2 comorbidities 1 1 1
C-erb-B2 absent 1.316 0.697 2.484 1.164 0.71 1.907 1.687 1.261 2.257
C-erb-B2  10% 1.86 0.179 19.317 4.329 1.093 17.143 1.546 0.526 4.543
C-erb-B2  10% 1 1 1
Ki-67  20% 3.245 1.604 6.565 0.93 0.568 1.524 1.732 1.307 2.295
Ki-67  20% 1 1 1
PVI absent 8.637 3.249 22.958 0.786 0.475 1.301 4.118 3.034 5.591
PVI present 1 1 1
Radiotherapy No radiotherapy
OR LCL UCL
YPM 0.45 0.27 0.75
OPM 0.5 0.293 0.854
EPM 1
0 positive lymph nodes 3.36 2.297 4.916
1–3 positive lymph nodes 3.686 2.49 5.456
4–9 positive lymph nodes 2.134 1.372 3.319
10 positive lymph nodes 1
Surgery—conservative 0.361 0.184 0.706
Surgery—mastectomy 9.056 4.54 18.064
Surgery—other 1
Surgery Conservative surgery Mastectomy
OR LCL UCL OR LCL UCL
YPM 1.114 0.475 2.617 1.05 0.426 2.584
OPM 1.516 0.603 3.811 1.243 0.47 3.284
EPM 1 1
YPM, OPM, EPM: Younger, older, elderly postmenopausal women; CT: chemotherapy; HT: hormone therapy; OR: odds ratio; ER/PgR: estrogen/progesterone receptor; CV: cardiovascular; PVI: peritumoral vascular
invasion; LCL: lower conﬁdence limit; UCL: upper conﬁdence limit.
a The estimates were derived from a multinomial regression model using SPSS. They are all to be interpreted relative to the baseline category in the multinomial model. For systemic therapy, the baseline reference
category is systemic therapy—both CT and HT; for radiotherapy, it is radiotherapy yes and for surgery, it is surgery—Other (see text). For radiotherapy, the OR/ are interpreted as from a logistic regression. So
Compared with the EPM group, a woman in the YPM group has an OR of not receiving radiotherapy of 0.45. The OR associated with lymph nodes and surgery reﬂect treatment practice. Relative to someone with
10 positive lymph nodes, the OR of receiving no radiotherapy is 3.67 for a woman with 1–3 positive lymph nodes. Compared with a women receiving other surgery, the OR of receiving no radiotherapy is high (9.06)
for a woman who had a mastectomy but low (0.36) for a woman receiving conservative surgery. Some of the OR/ are very large; or very small, reﬂecting the systematic structures in the use of systemic therapy. Patients
who are ER and PgR negative do not normally receive hormonal therapy. Compared with the EPM group, women in the YPM and OPM groups are much less likely (OR  0.007 and 0.020, respectively) of receiving
no systemic therapy relative to both CT and HT. For the other parameters, women with Ki-67  20 are much more likely to receive no CT or HT than women with Ki-67.  20 relative to receiving both CT and HT.
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fered an equal opportunity to receive appropriate
treatment.38 Elderly patients, suitable for breast con-
servation, are offered this type of treatment and inves-
tigational approaches are being developed to decrease
the distress of 6 weeks of daily radiotherapy by imple-
menting innovative, intraoperative, one-shot radio-
therapy.39 This time-saving treatment can have a sig-
niﬁcant impact on a patient and on the decision of the
physician to employ radiotherapy. All three groups of
patients were treated similarly, unless there was sig-
niﬁcant comorbidity to limit their overall likely sur-
vival. If older patients were suitable for breast conser-
vation, they were offered this mode of treatment, and
treatments administered did not differ from those ad-
ministered to their younger counterparts (Table 2).
Axillary surgery plays an established role in the staging
and treatment of breast carcinoma. The surgical man-
agement of the axilla in elderly patients has to be
determined on a case-by-case basis, which also takes
the patient’s wishes into consideration. The decision
will depend on the patient, on tumor characteristics,
on available technologies, and on local expertise. To
all patients with tumors  3 cm with a clinically neg-
ative axilla, we offer sentinel lymph node biopsy. Our
overall results with this technique indicate that senti-
nel lymph node biopsy can accurately predict the sta-
tus of the axilla, thus avoiding unnecessary ALND.35 In
patients with tumors  3 cm with clinically negative
axilla and in patients with any cT with clinically in-
volved axilla, we offer ALND Level I–III. These data are
noteworthy because other studies suggest that elderly
women are less likely to be offered or receive breast
conservation surgery.40,41 The most recent data favor
mastectomy as the most common choice for older
women,41 both for reasons related to the tumor itself
and to patient preference.
Elderly patients referred to surgery present with a
higher risk of disease recurrence (i.e., they have more
positive lymph nodes) and are likely to have an endo-
crine- responsive disease. Endocrine receptor positiv-
ity was similar among the three groups (78.6% vs.
82.5% vs. 81.3%, respectively, for the YPM, OPM, and
EPM groups), with a trend for EPM patients to have a
higher degree of ER and PgR expression in the tumor.
The proliferation index (Ki-67) did not differ among
the three groups, although PVI and overexpression of
HER-2/neu were different among the groups. Steroid
receptors, tumor proliferation, c-erb-B2 overexpres-
sion, and PVI are prognostic indicators and predictors
of treatment outcome, and thus might aid in decision-
making regarding the choice of adjuvant treatment.12
As expected, comorbid conditions were more often
recorded for EPM patients compared with YPM pa-
tients (Table 1; 65.7% vs. 49.2% and 32.7 respectively;
P  0.01). In the EPM group, the most common con-
dition with high impact of comorbidity was hyperten-
sion under active treatment (22.6%). Cardiovascular
disease was observed in 20.5% of the patients. Two or
more comorbid conditions occurred in 21.2% of EPM
patients. The presence of comorbidity in our study
inﬂuenced the choice of adjuvant treatment. Even if
several studies have shown that older patients re-
ceived less extensive treatment (e.g., adjuvant radio-
therapy and chemotherapy),42–44 little data exist on
treatment for older patients with breast carcinoma
with serious comorbid conditions because these pa-
tients generally are not eligible for clinical trials.28,44
Chemotherapy was recommended to 6.4% of EPM
patients compared with 35.4% of patients in the other
two groups. It is, however, typically indicated for pa-
tients with endocrine-nonresponsive disease, espe-
cially when axillary lymph nodes are involved. For
patients with endocrine-responsive tumors, endocrine
treatment was recommended to 74.4% of EPM pa-
tients, to 72.5% of YPM patients, and to 82.0% of OPM
patients. Conversely, no systemic therapy (either che-
motherapy or endocrine therapy) was recommended
to 19.1% of EPM patients compared with 5.4% and 4.7
% of patients in the two other groups (Table 2).
A differentiated approach to local and systemic
treatments in elderly patients with breast carcinoma
has been well documented.45–49 Even if several reports
showed that breast carcinoma prognosis is poor for
older women,48 this difference seems to be related to
failure to treat older patients in a similar manner to
their younger counterparts. A recent study showed
that both older and younger patients with locoregional
breast carcinoma fare equally well.49 Our data suggest
that age per se should not be the only factor in the
decision-making process for patients with cancer pa-
tients. In the elderly, the overall status of the patient,
more than the age itself, should be addressed when
treatment options are being considered. Acute and
chronic medical conditions, nutritional status, level of
activity, and disease-speciﬁc symptoms all need to be
considered. Only these concomitant factors, together
with the patient’s opinion, should inﬂuence the type
and extent of therapy. The goals of treatment in el-
derly patients should be the same as those in younger
patients. Studies of comprehensive treatments in pa-
tients  75 years, as well as in sick patients, should
probably be considered for the future. Finding reliable
and effective ways to include elderly patients with
comorbidities in clinical trials is a major challenge that
will need to be addressed in the years to come.50
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